

Pharnext's PLEODRUG™, PXT3003, to be Featured in Multiple Presentations at the 2017 Peripheral Nerve Society Meeting

*Status of ongoing pivotal Phase 3 trial for PXT3003
to be presented in oral and poster sessions*

Paris, France, 5:45pm, June 27, 2017 (CEST) – Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that the Company will present an update from its ongoing pivotal Phase 3 clinical trial evaluating lead PLEODRUG™ PXT3003, in development for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in a poster and at an oral session at the upcoming 2017 Peripheral Nerve Society Meeting. Additional data related to PXT3003 and CMT1A will also be featured in two posters at the meeting, which is being held on July 8-12 in Sitges, Spain.

- **Clinical Trials Update sessions - Tuesday July 11, 2017, 7:30am to 8:30am CEST**
 - **Oral Presentation** *“Status of the ongoing multi-center, randomised, double-blind, placebo controlled, pivotal phase III study to assess the efficacy and safety of PXT3003 for CMT1A (PLEO-CMT).”* R. Goedkoop et al.
 - **Presenter:** René Goedkoop, MD, Chief Medical Officer, Pharnext, Issy-les-Moulineaux, France

- **Poster Viewing Session #2 – Monday July 10, 2017**
 - **Poster P2_81 (abstract 34948)** *“Sensitivity to change of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) and Overall Neuropathy Limitation Scale (ONLS) in a database of French patients with CMT1A.”* J. Fouquier et al.

- **Poster Viewing Session #4 – Wednesday July 12, 2017**
 - **Poster P4_42 (abstract 34857)** *“PXT3003, a fixed combination of baclofen, naltrexone and sorbitol, for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A): status of a multicenter, double-blind, placebo-controlled, pivotal Phase III study (PLEOMCT).”* S. Attarian et al.
 - **Poster P4_58 (abstract 34930)** *“The combinational drug PXT3003 improves neuromuscular function in an animal model of Charcot-Marie-Tooth type 1A disease.”* T. Prukop et al.

All abstracts will be published in the Journal of the Peripheral Nervous System (JPNS) accessible at: www.wileyonlinelibrary.com/journal/JPNS

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug

discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

CONTACTS:

Pharnext

Xavier Paoli
Chief Commercial Officer
contact@pharnext.com
+33 (0)1 41 09 22 30

Pharnext

Pierre Schwich
Chief Financial Officer
investors@pharnext.com
+33 (0)1 41 09 22 30

Investor Relations (Europe)

MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252 22

Investor Relations (U.S.)

Stern Investor Relations, Inc.
Sarah McCabe
sarah@sternir.com
+1 212-362-1200

Financial Communication (France)

NewCap
Emmanuel Huyn
pharnext@newcap.eu
+33 (0)1 44 71 20 40

Media Relations (Europe)

ALIZE RP
Caroline Carmagnol
Margaux Pronost
pharnext@alizerp.com
+33 (0)1 44 54 36 64

Media Relations (U.S.)

Russo Partners
Tony Russo
Scott Santiamo
tony.russo@russopartnersllc.com
scott.Santiamo@russopartnersllc.com
+1 212-845-4251
+1 718-344-5843